Mercaptopurine and Vitamin k drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Mercaptopurine and Vitamin k. Common interactions include cerebral ischaemia among females and abnormal loss of weight among males.

The phase IV clinical study analyzes what interactions people who take Mercaptopurine and Vitamin k have. It is created by eHealthMe based on reports of 22 people who take Mercaptopurine and Vitamin k from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Nov, 30, 2022

22 people who take Mercaptopurine and Vitamin k together, and have interactions are studied.

What is Mercaptopurine?

Mercaptopurine has active ingredients of mercaptopurine. It is often used in crohn's disease. eHealthMe is studying from 20,129 Mercaptopurine users for its effectiveness, alternative drugs and more.

What is Vitamin k?

Vitamin k has active ingredients of vitamin k. It is often used in osteoporosis. eHealthMe is studying from 4,526 Vitamin k users for its effectiveness, alternative drugs and more.

Number of Mercaptopurine and Vitamin k reports submitted per year:

Common Mercaptopurine and Vitamin K drug interactions by gender *:

female:

Cerebral ischaemia
Superior sagittal sinus thrombosis
Transverse sinus thrombosis
Cytokine release syndrome
Febrile neutropenia
Hyperglycaemia
Urinary retention
Sinus tachycardia
Cholestasis
Drug clearance decreased

male:

Abnormal loss of weight
Abscess intestinal
Intussusception
Muscular weakness
Nausea
Neuromuscular toxicity
Pain in extremity
Pancreatic pseudocyst
Pancreatitis
Post procedural complication

Common Mercaptopurine and Vitamin K drug interactions by age *:

0-1:

n/a

2-9:

Eyelid ptosis
Muscular weakness
Neuromuscular toxicity
Pain in extremity
Tendon injury

10-19:

Transverse sinus thrombosis
Febrile neutropenia
Cytokine release syndrome
Hyperglycaemia
Urinary retention
Sinus tachycardia
Abnormal loss of weight
Cholestasis
Drug clearance decreased
Gastric perforation

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

Cognitive disorder
Drug ineffective
Hypoacusis

60+:

n/a

Common conditions people have *:

Acute Lymphocytic Leukemia (All) (cancer of the white blood cells characterized by excess lymphoblasts): 14 people, 63.64%
Pain: 10 people, 45.45%
Fever: 10 people, 45.45%
Nausea (feeling of having an urge to vomit): 9 people, 40.91%
Indigestion: 8 people, 36.36%
Hyperuricaemia (level of uric acid in the blood that is abnormally high): 8 people, 36.36%
Abdominal Pain: 8 people, 36.36%
B-Cell Lymphoma Refractory (blood cancer affecting b cells-relapsed): 3 people, 13.64%

* Approximation only. Some reports may have incomplete information.

Do you take Mercaptopurine and Vitamin k?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.